Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2017-2026)

1
Industry Research by Koncept Analytics
Global Non-Alcoholic Steatohepatitis (NASH) Drugs
Market Industry Analysis Outlook
-----------------------------------------
(2017-2026)
October 2017
2
Executive Summary
Non-alcoholic steatohepatitis or NASH is a form
of liver disease that causes inflammation and
accumulation of fat tissues in the liver. It
resembles alcoholic liver disease but occurs to
those who drink too little or no alcohol. NASH
shows no symptoms and is also known as a Silent
liver disease. NASH can lead to cirrhosis, in
which liver is permanently damaged and scarred
and after a certain point, no treatment can cure
it and thus lead to death. There are two types of
fatty liver disease alcoholic fatty liver
disease and non-alcoholic fatty liver disease
(NAFLD). When inflammation is present with
accumulation of fat in the liver then it is
referred as NASH. Obesity and diabetes are most
common cause of NASH disease. It is a challenge
for the patient to recognize the accumulation of
fat in the liver as patient experience no such
symptoms until reach the advanced stage of the
disease. The diagnosis of NASH includes blood
tests, MRI, X-rays and liver biopsy. Treatment of
NASH includes managing and improving the
condition of NASH from being worse and is
recommended to bring changes in lifestyle and
also use of off label drugs to control and manage
indications related to NASH. Currently there is
no approved drug in the market but is expected to
enter the market in 2020. Currently, there are
five potential Phase III drugs in the market
including Elafibranor, Ocaliva (OCA),
Cenicriviroc (CVC), Selonsertib and Aramchol. The
global NASH market is expected to show
significant growth after the introduction of
therapeutics drugs in 2020. Growth of market will
mainly be driven by increasing patient base, rise
in obese population, increasing type-2 diabetic
population and increasing health expenditure.
However, growth of market will also be hindered
by absence of effective diagnostics, costly
drugs, regulatory challenges and undefined
pathogenesis. The report Global NASH Drugs
Market Industry Analysis Outlook (2017-2026)
analyzes the development of this market, with
focus on the US and Europe region. The major
trends, growth drivers as well as issues being
faced by the market are discussed in detail in
this report. The four major players Genfit SA,
Intercept Pharmaceuticals, Inc., Allergan Plc.
(Tobira) and Gilead Sciences are being profiled
along with their key financials and strategies
for growth. The report contains a comprehensive
analysis of the global NASH market along with the
study of the regional markets.
3
Increased prevalence of obesity and diabetes
supported the growth of global NASH therapeutics
market
Global NASH Drugs Market Forecast by Value
(2017-2026)

• Global NASH drugs market is estimated to reach
  USbillion in the year 2026, increasing from
  USbillion in the year 2017, recording growth at
  a CAGR of .. for the period spanning 2017-2026.
• Global NASH off label drugs market is anticipated
  to reach US...billion in the year 2026,
  increasing from US...billion in the year 2017,
  recording growth at a CAGR of .. for the period
  spanning 2017-2026.
• In 2017, off label drugs are expected to account
  for share. In 2026, therapeutics drugs will
  account for followed by off label drugs with
  .. market share.

Global NASH Off Label Drugs Market Forecast by
Value (2017-2026)
Global NASH Drugs Market Forecast by Drug Class
(2017/2021/2026)
2021
2017
2026
4
Strong RD efforts by companies and
development of NASH diagnosis therapies
biomarkers will drive growth of global NASH
market
Global NASH Therapeutics Market Forecast by
Value (2020-2026)

• Global NASH therapeutics market is projected to
  reach US ..billion in the year 2026, increasing
  from US ..billion in the year 2020, recording
  growth at a CAGR of .. for the period spanning
  2020-2026.
• The US NASH therapeutics market is estimated to
  reach US ..billion in the year 2026, increasing
  from US ..billion in the year 2020, recording
  growth at a CAGR of .. for the period spanning
  2020-2026.
• Europe NASH therapeutics market is estimated to
  reach US ..billion in the year 2026, increasing
  from US ..billion in the year 2020, recording
  growth at a CAGR of .. for the period spanning
  2020-2026.

The US NASH Therapeutics Market Forecast by Value
(2020-2026)
Europe NASH Therapeutics Market Forecast by Value
(2020-2026)
5
For Report Purchase Click Belowhttp//www.koncep
tanalytics.com/Researchreport/global-fluff-pulp-ma
rket-industry-analysis-outlook-2017-2021-25464.asp
x
Disclaimer
Contact Us
This is a licensed product of Koncept Analytics.
You cannot reproduce, publish, distribute,
publicly display, sell or create other works from
this report or use them in any way for commercial
purpose without our prior permission. Further,
you cannot copy this material, by any means
(including electronic copies), for distribution
to others unless you have purchased the corporate
license of this report. We believe the sources
are reliable, but Koncept Analytics does not
warranty the accuracy or completeness of the
data. The data presented in the report is updated
at the publication date but is subject to change
at subsequent releases. All possible efforts have
been made to ensure accuracy of data. However,
investors should not completely rely on the
information given in this report and must make
decisions based on their own investment strategy,
risk management and capital adequacy.
Koncept Analytics CS-36, First Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T
91-120-4130959 M 91-9811715635
vikas_at_konceptanalytics.com
www.konceptanalytics.com